P
Paul H.M. Smits
Researcher at Netherlands Cancer Institute
Publications - 33
Citations - 1464
Paul H.M. Smits is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: DPYD & Population. The author has an hindex of 19, co-authored 33 publications receiving 1331 citations. Previous affiliations of Paul H.M. Smits include Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
Maarten J. Deenen,Didier Meulendijks,Annemieke Cats,Marjolein K. Sechterberger,Johan L. Severens,Henk Boot,Paul H.M. Smits,Hilde Rosing,Caroline M.P.W. Mandigers,Marcel Soesan,Jos H. Beijnen,Jan H.M. Schellens +11 more
TL;DR: In this paper, the feasibility, safety, and cost of DPYD*2A genotype-guided dosing were investigated for patients who intended to be treated with fluoropyrimidine-based chemotherapy.
Journal ArticleDOI
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer
Maarten J. Deenen,Jolien Tol,Artur M. Burylo,Valerie D. Doodeman,Anthonius de Boer,Andrew D. Vincent,Henk-Jan Guchelaar,Paul H.M. Smits,Jos H. Beijnen,Cornelis J. A. Punt,Jan H.M. Schellens,Annemieke Cats +11 more
TL;DR: The coding region of dihydropyrimidine dehydrogenase gene (DPYD) was sequenced in 45 cases with grade 3 or more capecitabine-related toxicity and in 100 randomly selected controls and eight SNPs were detected in the case–cohort analysis.
Journal ArticleDOI
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Corine Ekhart,Valerie D. Doodeman,Sjoerd Rodenhuis,Paul H.M. Smits,Jos H. Beijnen,Alwin D. R. Huitema +5 more
TL;DR: It is indicated that the presently evaluated variant alleles in the CYP2B6, CyP2C9, CYP3A4, CYp3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1 genes do not explain the interindividual variability in cyclophosphamide and 4-hydroxycyclophosphamate pharmacokinetics and are, probably, not the cause of the observed variability in toxicity.
Journal ArticleDOI
Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF10 PCR and HPV genotyping
W. G. V. Quint,Ger H. A. Scholte,L. J. van Doorn,Kleter Bernhard,Paul H.M. Smits,Jan H.N. Lindeman +5 more
TL;DR: Analysis of cervical scrapes accurately reflects the spectrum of HPV genotypes in the patient's cervical region, even with a sampling interval between the cervical scrape and the biopsy specimen.
Journal ArticleDOI
An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment
Corine Ekhart,Sjoerd Rodenhuis,Paul H.M. Smits,Jos H. Beijnen,Jos H. Beijnen,Alwin D. R. Huitema +5 more
TL;DR: The most important polymorphisms shown to influence survival after cancer treatment are polymorphisms in the genes encoding the phase II detoxification enzymes glutathione-S-transferases, and it appears that GSTM1 null and GSTT1 null have a clear association with longer overall survival in patients with different malignancies who are treated with substrates for these GSTs.